Skip to main content

REMEDi4ALL researchers based at the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) and Fraunhofer Institute for Algorithms and Scientific Computing in Germany have recently published an article in Nature Scientific Data which explores the streamlining of publicly available databases for the development of new drugs.

Yojana Gadiya and colleagues at Fraunhofer Institutes explored the publicly available database of patent compounds, SureChEMBL to investigate the role of patent documents in drug discovery, evaluate the FAIRness (Findability, Accessibility, Interoperability, and Reusability) of chemical compounds, and analyse any drug-like properties of compounds within the SureChEMBL database.
Researchers found that, to optimise the drug discovery process, integration between public databases including PubChem and ChEMBL, which contain information on chemical molecules, and SureChEMBL was essential. Moreover, researchers found that SureChEMBL data could be useful when assessing the feasibility of certain compounds as drugs. However, researchers must take care to carefully select only relevant compounds from the SureChEMBL database.
Collectively, researchers concluded that using information from another public database, SureChEMBL, can enhance drug discovery efforts by providing access to a wider array of potential compounds in the form of chemical molecules.
This research could enhance the efficiency and scope of drug discovery by providing researchers with both access and awareness of resources to develop or repurpose drugs, facilitate understanding and utilisation of patent drugs and provide opportunities for discovering new and effective drugs.